Cargando…

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

BACKGROUND: Cancer-related disturbances in myeloid lineage development, marked by high levels of myeloid-derived suppressor cells (MDSC) and impaired dendritic cell (DC) development, are associated with poor clinical outcome due to immune escape and therapy resistance. Redressing this balance may th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santegoets, Saskia JAM, Stam, Anita GM, Lougheed, Sinéad M, Gall, Helen, Jooss, Karin, Sacks, Natalie, Hege, Kristen, Lowy, Israel, Scheper, Rik J, Gerritsen, Winald R, van den Eertwegh, Alfons JM, de Gruijl, Tanja D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507359/ https://www.ncbi.nlm.nih.gov/pubmed/26196012 http://dx.doi.org/10.1186/s40425-014-0031-3

Ejemplares similares

S48. Biomarker development for ipilimumab and prostate GVAX treatment
por: de Gruijl, T, et al.
Publicado: (2014)

IL-21 promotes the expansion of CD27(+)CD28(+) tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells
por: Santegoets, Saskia JAM, et al.
Publicado: (2013)

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells
por: van Dodewaard-de Jong, Joyce M., et al.
Publicado: (2015)

Functional characterization of a STAT3-dependent dendritic cell-derived CD14(+) cell population arising upon IL-10-driven maturation
por: Lindenberg, Jelle J., et al.
Publicado: (2013)

Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
por: de Gruijl, Tanja D., et al.
Publicado: (2008)

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
por: Boudewijns, Steve, et al.
Publicado: (2016)

Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition
por: Oosterhoff, Dinja, et al.
Publicado: (2012)

IL-10 Conditioning of Human Skin Affects the Distribution of Migratory Dendritic Cell Subsets and Functional T Cell Differentiation
por: Lindenberg, Jelle J., et al.
Publicado: (2013)

Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial
por: Koster, Bas D., et al.
Publicado: (2019)

Dual-Phase PET-CT to Differentiate [(18)F]Fluoromethylcholine Uptake in Reactive and Malignant Lymph Nodes in Patients with Prostate Cancer
por: Oprea-Lager, Daniela E., et al.
Publicado: (2012)

Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy
por: Gerritsen, Winald R., et al.
Publicado: (2011)

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node
por: van den Hout, Mari F. C. M., et al.
Publicado: (2016)

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
por: Cha, Edward, et al.
Publicado: (2013)

Comparison of proteomic and genomic analyses of vaccine cell lines shows men receiving prostate gvax immunotherapy develop increased humoral responses to common cell line proteins relative to mutated proteins
por: Hulett, Tyler, et al.
Publicado: (2014)

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2011)

Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor
por: van Cruijsen, H., et al.
Publicado: (2007)

IL-21 in cancer immunotherapy: At the right place at the right time
por: Santegoets, Saskia JAM, et al.
Publicado: (2013)

Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy
por: van den Ancker, Willemijn, et al.
Publicado: (2013)

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
por: Lipson, Evan J, et al.
Publicado: (2015)

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
por: Yarchoan, Mark, et al.
Publicado: (2019)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
por: Revicki, Dennis A, et al.
Publicado: (2012)

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients
por: Colston, Elizabeth, et al.
Publicado: (2018)

Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
por: Westdorp, Harm, et al.
Publicado: (2014)

Adjuvant treatment of early-stage melanoma by local i.d. administration of low-dose CpG-B and GM-CSF increases recurrence-free survival: long-term follow-up of three randomized clinical trials
por: de Gruijl, Tanja D, et al.
Publicado: (2015)

Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience
por: Gao, Jianjun, et al.
Publicado: (2015)

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
por: Boudadi, Karim, et al.
Publicado: (2018)

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy
por: Graff, Julie N., et al.
Publicado: (2020)

Pre-operative intradermal administration of CpG-B ± GM-CSF in stage I-III melanoma patients arms the sentinel lymph node: evidence for reduced tumor spread
por: van den Hout, Mari F, et al.
Publicado: (2013)

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
por: van der Doelen, Maarten J., et al.
Publicado: (2021)

Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy
por: Qin, L, et al.
Publicado: (2013)

Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancreatic cancer
por: Nair, Nitya, et al.
Publicado: (2015)

Ipilimumab
Publicado: (2012)

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
por: Cabel, Luc, et al.
Publicado: (2017)

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
por: Maki, Robert G., et al.
Publicado: (2013)

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2021)

Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2022)

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer
por: Scholz, Mark, et al.
Publicado: (2017)

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
por: Sinha, Meenal, et al.
Publicado: (2021)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016)

Proteasome inhibitors as experimental therapeutics of autoimmune diseases
por: Verbrugge, Sue Ellen, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3gf24l6nlgr9ldvfg53kmvmt0d